Review of the History and Current Status of Cell-Transplant Approaches for the Management of Neuropathic Pain

Table 2

Naturally occurring (tumor) cell lines.

Source	Pain model	Results
Tumor Cell Lines: Rat PC12 [74]; Encapsulated PC12 [272]; Mouse B16 [81]; Human NB69 [83]; AtT-20 [84, 273]; Encapsulated AtT-20 [85],; Neuro2A [85]; Encapsulated Neuro2A [1327]; P19 [87],	Tail-flick or chemical induction [81, 84, 85, 87, 88]; Acute [81, 84, 85, 88, 273]; Partial nerve injury (CCI) [83, 272, 274]; Formalin [87]	(i) Analgesic [85, 88]; (ii) Reduced opioid tolerance [84]; (iii) Antinociceptive [81, 83, 84, 273, 274]; (iv) Reduced cold allodynia [83, 272]
Bio-engineered—AtT-20/hENK [84, 273]; Encapsulated Neuro2A/POMC [86]; Autologous rat macrophages/proENK [274]; PC12/SHG peptide [75]	Tail-flick or chemical induction [84, 273]; Formalin [75]	(i) Increased ACTH release with TET-ON stimulation [86]; (ii) Reduced Phase II formalin-induced responses [75]